PCK2 and cancer: Consistently, potentiation of resistance to glucose deprivation by the loss of PKC-ζ, a tumor suppressor [10], required PEPCK-M activity demonstrating that this enzyme serves an adaptative role in cancer metabolism, with significance in tumor growth, and further validates its potential as a therapeutic target.